{"id":"W4404194478","doi":"10.1177/17562848241293643","title":"Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Genentech; UCB Pharma; Sun Pharma; Astellas Pharma; Celltrion; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Gilead Sciences; GlaxoSmithKline; Tillotts Pharma; Amgen; Dr. Falk Pharma; Pfizer; Celgene","keywords":"Medicine; Ulcerative colitis; Adverse effect; Phases of clinical research; Phase (matter); Internal medicine; Clinical trial; Gastroenterology; Intensive care medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001334836,0.0002721636,0.0006951067,0.0002087213,0.00007284417,0.000008156755,0.0002008382,0.0001390867,0.00001944477],"category_scores_gemma":[0.00008258831,0.000202128,0.0001441032,0.0002126389,0.0003775803,0.00004685571,0.0001323506,0.0002180012,2.338279e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003414848,"about_ca_system_score_gemma":0.00005826117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001360675,"about_ca_topic_score_gemma":0.002240535,"domain_scores_codex":[0.9967588,0.00120261,0.0008861829,0.000613944,0.0001534474,0.0003849701],"domain_scores_gemma":[0.9990271,0.00009452341,0.0003262556,0.0003752371,0.00006439331,0.0001124648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02561785,0.001004472,0.9487066,0.00004700048,0.0008633035,0.00002588294,0.0004494619,0.0004568745,0.001258695,0.0000210239,0.000001601435,0.02154727],"study_design_scores_gemma":[0.01965151,0.004493609,0.9712034,0.0000754175,0.0006691428,0.000003633902,0.0001665527,0.003062416,0.0002446357,0.0001318929,0.0001300151,0.0001677109],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977189,0.0002701222,0.0008848521,0.00004815294,0.0001673179,0.0007248129,0.0001684381,0.000008612794,0.000008767955],"genre_scores_gemma":[0.9987256,0.0005686266,0.0001279741,0.0003154021,0.00004418638,0.00006842157,0.0001113957,0.0000255001,0.00001292726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0224969,"threshold_uncertainty_score":0.8242541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01593308882847572,"score_gpt":0.3510217434978404,"score_spread":0.3350886546693647,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}